Flag of the European Union EU Clinical Trials Register Help

Clinical trials for topotecan hydrochloride

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: topotecan hydrochloride. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-002074-22 Sponsor Protocol Number: UM2005/00201/00 Start Date*: 2006-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.
    Medical condition: Brain metastases from primary non-small cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003726-17 Sponsor Protocol Number: M16-289 Start Date*: 2017-06-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have Firs...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) BE (Completed) LV (Completed) NL (Completed) GR (Completed) BG (Completed) PL (Completed) FR (Completed) ES (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001069-14 Sponsor Protocol Number: ABC-2007-SCLC-02 Start Date*: 2008-02-15
    Sponsor Name:Aktion Bronchialkarzinom e.V.
    Full Title: A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second...
    Medical condition: Prospective randomized multi-center open label phase II study to determine the antitumoral activity and the feasibility of a combination therapy with Hycamtin/Carboplatin administered 5-days versus...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002326-24 Sponsor Protocol Number: ALKS4230-007 Start Date*: 2023-02-13
    Sponsor Name:Mural Oncology, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial O...
    Medical condition: Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Completed) IT (Trial now transitioned) NO (Trial now transitioned) AT (Ongoing) LT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001842-19 Sponsor Protocol Number: GINECO-CE103 Start Date*: 2008-08-14
    Sponsor Name:ARCAGY
    Full Title: Etude de phase I / II de l’association carboplatine et topotecan oral hebdomadaire chez des patientes atteintes de cancer du col de l’utérus métastatique ou en rechute.
    Medical condition: ASSOCIATION CARBOPLATINE ET TOPOTECAN ORAL HEBDOMADAIRE CHEZ DES PATIENTES ATTEINTES DE CANCER DU COL DE L’UTERUS METASTATIQUE OU EN RECHUTE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064444 Invasive cervix cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003130-27 Sponsor Protocol Number: 2015/2294 Start Date*: 2017-05-15
    Sponsor Name:Gustave Roussy
    Full Title: An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chem...
    Medical condition: Very High Risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008126 Cerebral neuroblastoma LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003989-18 Sponsor Protocol Number: AMR PH GL 2007 CL 001 Start Date*: 2008-04-24
    Sponsor Name:Celgene Corporation
    Full Title: A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...
    Medical condition: Extensive or limited and sensitive or refractory SCLC after failure of first-line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed) HU (Completed) NL (Completed) AT (Completed) CZ (Completed) IT (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005251-39 Sponsor Protocol Number: PM1183-C-004-14 Start Date*: 2015-06-15
    Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal
    Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)
    Medical condition: Platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) AT (Completed) BE (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000350-19 Sponsor Protocol Number: R2810-ONC-1676 Start Date*: 2017-11-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma
    Medical condition: recurrent or metastatic, platinum-refractory cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000758-20 Sponsor Protocol Number: DIV-SCLC-301 Start Date*: 2017-06-21
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
    Medical condition: relapsed or refractory small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Completed) LT (Completed) FR (Completed) PL (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002172-16 Sponsor Protocol Number: PM1183-B-002-11 Start Date*: 2011-10-18
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients.
    Medical condition: Platinum-Resistant / Refractory Advanced Ovarian Cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001848-21 Sponsor Protocol Number: ALRN-6924-1-03 Start Date*: 2019-09-12
    Sponsor Name:Aileron Therapeutics, Inc.
    Full Title: A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
    Medical condition: Small Cell Lung Cancer and Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004585-15 Sponsor Protocol Number: Cat-Ovar_2011 Start Date*: 2012-11-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca...
    Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001436-12 Sponsor Protocol Number: CSET 2008/1378 Start Date*: 2008-07-04
    Sponsor Name:Institut Gustave Roussy
    Full Title: Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours.
    Medical condition: Neuroblastoma and Other pediatric solid tumours.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066595 Neuroblastoma recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) NL (Ongoing) AT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003415-31 Sponsor Protocol Number: ARD12166 Start Date*: 2012-01-25
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) NO (Completed) IT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001440-22 Sponsor Protocol Number: LIVONCO2012/001 Start Date*: 2013-06-26
    Sponsor Name:
    Full Title: A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)
    Medical condition: Histologically/cytologically confirmed diagnosis of metastatic NSCLC. Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003509-80 Sponsor Protocol Number: IMGN853-0416 Start Date*: 2020-09-07
    Sponsor Name:ImmunoGen, Inc.
    Full Title: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Periton...
    Medical condition: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Completed) PL (Completed) PT (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:22:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA